Summary
Cencora, Inc. (COR), formerly AmerisourceBergen Corporation, reported a significant increase in revenue and operating income for the quarter ended December 31, 2020, compared to the prior year. Revenue grew by 9.7% to $52.5 billion, primarily driven by the Pharmaceutical Distribution Services segment, which saw higher sales of specialty products, including COVID-19 treatments, and organic growth from key customers. This top-line growth, coupled with improved gross profit margins and a favorable comparison to operating expenses (which were reduced by a prior year impairment charge), led to a substantial 107.7% increase in operating income to $547.2 million. Investors should note the company's ongoing significant opioid litigation, for which a substantial liability has been accrued, though the ultimate resolution and potential for further impact remain a key area of focus. Additionally, the company announced a major acquisition in January 2021 of a majority of Walgreens Boots Alliance's Alliance Healthcare businesses for approximately $6.5 billion, which is expected to significantly expand its international presence. While the company generated strong operating cash flow, it also has substantial debt obligations and commitments, including those related to the opioid litigation and the upcoming acquisition, necessitating careful management of its capital resources.
Financial Highlights
56 data points| Revenue | $52.52B |
| Cost of Revenue | $51.06B |
| Gross Profit | $1.45B |
| SG&A Expenses | $735.07M |
| Operating Income | $547.23M |
| Net Income | $374.85M |
| EPS (Basic) | $1.83 |
| EPS (Diluted) | $1.81 |
| Shares Outstanding (Basic) | 204.68M |
| Shares Outstanding (Diluted) | 206.80M |
Key Highlights
- 1Revenue increased by 9.7% to $52.5 billion for the quarter ended December 31, 2020, driven by strong performance in the Pharmaceutical Distribution Services segment, including sales of specialty products and COVID-19 treatments.
- 2Operating income saw a substantial increase of 107.7% to $547.2 million, benefiting from higher gross profits and a reduction in operating expenses compared to the prior year, which included a significant impairment charge.
- 3The company has accrued a $6.6 billion liability for opioid-related litigation, with advanced discussions for a global settlement, indicating a significant ongoing legal and financial contingency.
- 4A major strategic move was announced: the acquisition of Walgreens Boots Alliance's Alliance Healthcare businesses for approximately $6.5 billion, signaling significant international expansion and integration efforts.
- 5Shareholders received increased dividends, with the quarterly dividend raised by 5% to $0.44 per share.
- 6Despite a significant increase in accounts payable, the company's cash provided by operating activities more than doubled year-over-year to $903.1 million, reflecting improved working capital management.